Floatz logo

Erythromycin

Classic Familial Adenomatous Polyposis

michal rollSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Classic Familial Adenomatous Polyposis cohort.

Asset / SponsorPhaseRating
Eflornithine
Cancer Prevention Pharmaceuticals, Inc.
Phase 3BB
EPA
S.L.A. Pharma AG
Phase 3BB
Azithromycin
Tel-Aviv Sourasky Medical Center
Phase 4BB
Sulindac
Cancer Prevention Pharmaceuticals, Inc.
Phase 3BB
Celecoxib
Yonsei University
Phase 3BB

View all 25 →

Same molecule, other indications

Erythromycin is also rated in:

colorectal cancerDormant
B
Indicative · Phase 2
57 / 100
View asset →
obesity disorderActive
CCC
Indicative · Phase 4
54 / 100
View asset →
non-small cell lung carcinomaActive
CCC
Indicative · Phase 3
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →